Bone-Targeted Agents and Metastasis Prevention

Area of Science:

• Oncology
• Pharmacology
• Bone Metastasis Research

Background:

• Bone-targeted treatments, including bisphosphonates and denosumab, are crucial in managing metastatic breast cancer.
• The impact of these agents on bone physiology and the metastatic process is extensively studied.
• Previous adjuvant trials with bisphosphonates in early breast cancer yielded variable outcomes, suggesting patient-specific factors influence efficacy.

Purpose of the Study:

• To investigate the influence of patient age and menopausal status on the efficacy of adjuvant bisphosphonates in early breast cancer.
• To analyze individual patient data from all available randomized trials to confirm or refute observed variable outcomes.
• To guide clinical practice regarding the use of bone-targeted agents in breast cancer adjuvant therapy.

Main Methods:

• A comprehensive meta-analysis of individual patient data from all relevant randomized trials was conducted.
• The analysis specifically examined outcomes based on menopausal status (premenopausal vs. postmenopausal women).
• Disease recurrence and breast cancer mortality were the primary endpoints assessed.

Main Results:

• Adjuvant bisphosphonates demonstrated no significant benefit in premenopausal women.
• A highly significant improvement in bone recurrence (RR = 0.72) and breast cancer mortality (RR = 0.82) was observed in 11,767 postmenopausal women.
• These findings support the efficacy of bisphosphonates in a specific patient subgroup.

Conclusions:

• Clinical guidelines should incorporate adjuvant bisphosphonates for osteoclast inhibition in routine care for eligible postmenopausal women.
• The differing outcomes between bisphosphonates and denosumab suggest potential "off-target" effects of bisphosphonates on immune function may be critical.
• Further research into predictive biomarkers, such as MAF, is warranted to identify patients who can benefit from bisphosphonate therapy.